These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 1353337)
21. Neuroactive peptides exist in the midbrain dopaminergic neurons that contain calbindin-D28k. German DC; Liang CL Neuroreport; 1993 May; 4(5):491-4. PubMed ID: 8513124 [TBL] [Abstract][Full Text] [Related]
22. The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson's disease. Yuan HH; Chen RJ; Zhu YH; Peng CL; Zhu XR Mol Neurobiol; 2013 Feb; 47(1):117-22. PubMed ID: 22923348 [TBL] [Abstract][Full Text] [Related]
23. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Rodríguez M; Barroso-Chinea P; Abdala P; Obeso J; González-Hernández T Exp Neurol; 2001 May; 169(1):163-81. PubMed ID: 11312569 [TBL] [Abstract][Full Text] [Related]
24. Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys. Masilamoni GJ; Groover O; Smith Y Neurobiol Dis; 2017 Apr; 100():9-18. PubMed ID: 28042095 [TBL] [Abstract][Full Text] [Related]
25. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Gibb WR Brain Res; 1992 May; 581(2):283-91. PubMed ID: 1382801 [TBL] [Abstract][Full Text] [Related]
26. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820 [TBL] [Abstract][Full Text] [Related]
27. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423 [TBL] [Abstract][Full Text] [Related]
28. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Varastet M; Riche D; Maziere M; Hantraye P Neuroscience; 1994 Nov; 63(1):47-56. PubMed ID: 7898660 [TBL] [Abstract][Full Text] [Related]
29. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373 [TBL] [Abstract][Full Text] [Related]
31. Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys. Lavoie B; Parent A; Bédard PJ Can J Neurol Sci; 1991 Aug; 18(3 Suppl):373-5. PubMed ID: 1933683 [TBL] [Abstract][Full Text] [Related]
32. The neurotoxin MPTP increases calbindin-D28k levels in mouse midbrain dopaminergic neurons. Ng MC; Iacopino AM; Quintero EM; Marches F; Sonsalla PK; Liang CL; Speciale SG; German DC Brain Res Mol Brain Res; 1996 Mar; 36(2):329-36. PubMed ID: 8965654 [TBL] [Abstract][Full Text] [Related]
33. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399 [TBL] [Abstract][Full Text] [Related]
34. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. McRitchie DA; Hardman CD; Halliday GM J Comp Neurol; 1996 Jan; 364(1):121-50. PubMed ID: 8789281 [TBL] [Abstract][Full Text] [Related]
35. The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. Luk KC; Rymar VV; van den Munckhof P; Nicolau S; Steriade C; Bifsha P; Drouin J; Sadikot AF J Neurochem; 2013 Jun; 125(6):932-43. PubMed ID: 23331067 [TBL] [Abstract][Full Text] [Related]
36. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. McRitchie DA; Cartwright HR; Halliday GM Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172 [TBL] [Abstract][Full Text] [Related]
37. Gangliosides and parkinsonism. Herrero MT; Kastner A; Perez-Otaño I; Hirsch EC; Luquin MR; Javoy-Agid F; Del Río J; Obeso JA; Agid Y Neurology; 1993 Oct; 43(10):2132-4. PubMed ID: 8413979 [TBL] [Abstract][Full Text] [Related]
38. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease? Luquin MR; Saldise L; Guillén J; Belzunegui S; San Sebastián W; Izal A; Garrido P; Vázquez M Exp Neurol; 2006 Oct; 201(2):407-15. PubMed ID: 16806173 [TBL] [Abstract][Full Text] [Related]
39. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211 [TBL] [Abstract][Full Text] [Related]
40. Calbindin-D28k-containing neurons in the human hypothalamus: relationship to dopaminergic neurons. Sanghera MK; Zamora JL; German DC Neurodegeneration; 1995 Dec; 4(4):375-81. PubMed ID: 8846230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]